Dr. Rastogi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Meyran Ave
Ste 318
Pittsburgh, PA 15213Phone+1 412-383-1650Fax+1 412-641-1085
Education & Training
- UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2000 - 2003
- Saint Joseph HospitalResidency, Internal Medicine, 1997 - 2000
- Wright State University Boonshoft School of MedicineClass of 1997
Certifications & Licensure
- PA State Medical License 2003 - 2024
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Publications & Presentations
PubMed
- 88 citationsEffect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial.Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, Timothy J Whelan, Marguerite Ennis
JAMA. 2022-05-24 - 420 citationsAbemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Stephen R. D. Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martín
Journal of Clinical Oncology. 2020-09-20 - 478 citationsAddition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a ra...Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M. Sikov, Hope S. Rugo
The Lancet. Oncology. 2018-04-01
Press Mentions
- Gene Assay for MammaPrint May Predict Responses to Extended Letrozole in Low-Risk Breast Cancer SubsetsAugust 30th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: